CRISPR/Cas9-based genome editing in the era of CAR T cell immunotherapy

References

• Kuwana Y, Asakura Y, Utsunomiya N, Nakanishi M, Arata Y, Itoh S, Nagase F, Kurosawa Y. Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions. Biochem Biophys Res Commun. 1987;149:960–68.
   PubMed Web of Science ®Google Scholar
• Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A. 1989;86:10024–28.
   PubMed Web of Science ®Google Scholar
• Irving BA, Weiss A. The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. Cell. 1991;64:891–901.
   PubMed Web of Science ®Google Scholar
• June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359:1361–65. doi:10.1126/science.aar6711.
   PubMed Web of Science ®Google Scholar
• Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725–33. doi:10.1056/NEJMoa1103849.
   PubMed Web of Science ®Google Scholar
• Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3:95ra73. doi:10.1126/scitranslmed.3002842.
   PubMed Web of Science ®Google Scholar
• Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507–17. doi:10.1056/NEJMoa1407222.
   PubMed Web of Science ®Google Scholar
• Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439–48. doi:10.1056/NEJMoa1709866.
   PubMed Web of Science ®Google Scholar
• Park JH, Riviere I, Gonen M, Wang X, Senechal B, Curran KJ, Sauter C, Wang Y, Santomasso B, Mead E, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378:449–59. doi:10.1056/NEJMoa1709919.
   PubMed Web of Science ®Google Scholar
• Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW,  Bagg A, Marcucci KT, Shen A, Gonzalez V, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Science translational medicine. 2015;7:303ra139. doi:10.1126/scitranslmed.aad3106.
   Google Scholar
• Mullard A. FDA approves first CAR T therapy. Nat Rev Drug Discovery. 2017;16:669.
   Web of Science ®Google Scholar
• Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak O, Brogdon JL, Pruteanu-Malinici I, Bhoj V, Landsburg D, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017;377:2545–54. doi:10.1056/NEJMoa1708566.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531–44. doi:10.1056/NEJMoa1707447.
   PubMed Web of Science ®Google Scholar
• Garfall AL, Maus MV, Hwang WT, Lacey SF, Mahnke YD, Melenhorst JJ, Zheng Z, Vogl DT, Cohen AD, Weiss BM, et al. Chimeric antigen receptor T cells against CD19 for multiple myeloma. N Engl J Med. 2015;373:1040–47. doi:10.1056/NEJMoa1504542.
   PubMed Web of Science ®Google Scholar
• Garfall AL, Stadtmauer EA, Hwang WT, Lacey SF, Melenhorst JJ, Krevvata M, Carroll MP, Matsui WH, Wang Q, Dhodapkar MV, et al. Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight. 2018;3. doi:10.1172/jci.insight.97941
   PubMed Web of Science ®Google Scholar
• Ramos CA, Savoldo B, Torrano V, Ballard B, Zhang H, Dakhova O, Liu E, Carrum G, Kamble RT, Gee AP, et al. Clinical responses with T lymphocytes targeting malignancy-associated kappa light chains. J Clin Invest. 2016;126:2588–96. doi:10.1172/JCI86000.
   PubMed Web of Science ®Google Scholar
• Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, Boesteanu AC, Wang Y, O’Connor RS, Hwang W-T, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24:563–71. doi:10.1038/s41591-018-0010-1.
   PubMed Web of Science ®Google Scholar
• Singh N, Perazzelli J, Grupp SA, Barrett DM. Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies. Sci Transl Med. 2016;8:320ra3. doi:10.1126/scitranslmed.aaf0746.
   PubMed Web of Science ®Google Scholar
• Fraietta JA, Beckwith KA, Patel PR, Ruella M, Zheng Z, Barrett DM, Lacey SF, Melenhorst JJ, McGettigan SE, Cook DR, et al. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. 2016;127:1117–27. doi:10.1182/blood-2015-11-679134.
   PubMed Web of Science ®Google Scholar
• Ghassemi S, Nunez-Cruz S, O’Connor RS, Fraietta JA, Patel PR, Scholler J, Barrett DM, Lundh SM, Davis MM, Bedoya F, et al. Reducing ex vivo culture improves the antileukemic activity of Chimeric Antigen Receptor (CAR) T cells. Cancer Immunol Res. 2018;6:1100–09. doi:10.1158/2326-6066.CIR-17-0405.
   PubMed Web of Science ®Google Scholar
• Long KB, Young RM, Boesteanu AC, Davis MM, Melenhorst JJ, Lacey SF, DeGaramo DA, Levine BL, Fraietta, JA. CAR T cell therapy of non-hematopoietic malignancies: detours on the road to clinical success. Front Immunol. 2018;9.
   Web of Science ®Google Scholar
• Knochelmann HM, Smith AS, Dwyer CJ, Wyatt MM, Mehrotra S, Paulos CM. CAR T cells in solid tumors: blueprints for building effective therapies. Front Immunol. 2018;9:1740. doi:10.3389/fimmu.2018.01740.
   PubMed Web of Science ®Google Scholar
• Schmidts A, Maus MV. Making CAR T cells a solid option for solid tumors. Front Immunol. 2018;9:2593. doi:10.3389/fimmu.2018.02593.
   PubMed Web of Science ®Google Scholar
• D’Aloia MM, Zizzari IG, Sacchetti B, Pierelli L, Alimandi M, Barbati C, Morello F, Alfè M, Di Blasio G, Gargiulo V, et al. CAR-T cells: the long and winding road to solid tumors. Cell Death Dis. 2018;9:282. doi:10.1038/s41419-018-1111-y.
   PubMed Web of Science ®Google Scholar
• Mali P, Esvelt KM, Church GM. Cas9 as a versatile tool for engineering biology. Nat Methods. 2013;10:957–63. doi:10.1038/nmeth.2649.
   PubMed Web of Science ®Google Scholar
• Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S, Romero DA, Horvath P. CRISPR provides acquired resistance against viruses in prokaryotes. Science. 2007;315:1709–12. doi:10.1126/science.1138140.
   PubMed Web of Science ®Google Scholar
• Horvath P, Barrangou R. CRISPR/Cas, the immune system of bacteria and archaea. Science. 2010;327:167–70. doi:10.1126/science.1179555.
   PubMed Web of Science ®Google Scholar
• Wiedenheft B, Sternberg SH, Doudna JA. RNA-guided genetic silencing systems in bacteria and archaea. Nature. 2012;482:331–38. doi:10.1038/nature10886.
   PubMed Web of Science ®Google Scholar
• Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell. 2014;157:1262–78. doi:10.1016/j.cell.2014.05.010.
   PubMed Web of Science ®Google Scholar
• Deltcheva E, Chylinski K, Sharma CM, Gonzales K, Chao Y, Pirzada ZA, Eckert MR, Vogel J, Charpentier E. CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature. 2011;471:602–07. doi:10.1038/nature09886.
   PubMed Web of Science ®Google Scholar
• Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337:816–21. doi:10.1126/science.1225829.
   PubMed Web of Science ®Google Scholar
• Lillestol RK, Shah SA, Brugger K, Redder P, Phan H, Christiansen J, Garrett RA. CRISPR families of the crenarchaeal genus Sulfolobus: bidirectional transcription and dynamic properties. Mol Microbiol. 2009;72:259–72. doi:10.1111/j.1365-2958.2009.06641.x.
   PubMed Web of Science ®Google Scholar
• Deveau H, Barrangou R, Garneau JE, Labonte J, Fremaux C, Boyaval P, Romero DA, Horvath P, Moineau S. Phage response to CRISPR-encoded resistance in Streptococcus thermophilus. J Bacteriol. 2008;190:1390–400. doi:10.1128/JB.01412-07.
   PubMed Web of Science ®Google Scholar
• Doudna JA, Charpentier E, Duzhko VV, Russell TP, Emrick T Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014;346:1258096. doi:10.1126/science.1255826.
   PubMed Web of Science ®Google Scholar
• Jiang F, Doudna JA. CRISPR-Cas9 structures and mechanisms. Annu Rev Biophys. 2017;46:505–29. doi:10.1146/annurev-biophys-062215-010822.
   PubMed Web of Science ®Google Scholar
• Shi J, Wang E, Milazzo JP, Wang Z, Kinney JB, Vakoc CR. Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains. Nat Biotechnol. 2015;33:661–67. doi:10.1038/nbt.3235.
   PubMed Web of Science ®Google Scholar
• Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339:819–23. doi:10.1126/science.1231143.
   PubMed Web of Science ®Google Scholar
• Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE, Church GM. RNA-guided human genome engineering via Cas9. Science. 2013;339:823–26. doi:10.1126/science.1232033.
   PubMed Web of Science ®Google Scholar
• Adli M. The CRISPR tool kit for genome editing and beyond. Nat Commun. 2018;9:1911. doi:10.1038/s41467-018-04252-2.
   PubMed Web of Science ®Google Scholar
• Ren J, Zhang X, Liu X, Fang C, Jiang S, June CH, Zhao Y. A versatile system for rapid multiplex genome-edited CAR T cell generation. Oncotarget. 2017;8:17002–11. doi:10.18632/oncotarget.15218.
   PubMedGoogle Scholar
• Torikai H, Reik A, Soldner F, Warren EH, Yuen C, Zhou Y, Crossland DL, Huls H, Littman N, Zhang Z, et al. Toward eliminating HLA class I expression to generate universal cells from allogeneic donors. Blood. 2013;122:1341–49. doi:10.1182/blood-2013-03-478255.
   PubMed Web of Science ®Google Scholar
• Choi EI, Reimann KA, Letvin NL. In vivo natural killer cell depletion during primary simian immunodeficiency virus infection in rhesus monkeys. J Virol. 2008;82:6758–61. doi:10.1128/JVI.02277-07.
   PubMed Web of Science ®Google Scholar
• Chong EA, Melenhorst JJ, Lacey SF, Ambrose DE, Gonzalez V, Levine BL, June CH, Schuster SJ. PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. Blood. 2017;129:1039–41. doi:10.1182/blood-2016-09-738245.
   PubMed Web of Science ®Google Scholar
• Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, van Leeuwen DG, Drakes DJ, Song M, Miele MM, Li Z, Wang P, et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol. 2018;36:847–56. doi:10.1038/nbt.4195.
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509–20. doi:10.1056/NEJMoa1500596.
   PubMed Web of Science ®Google Scholar
• Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, Zahurak M, Yang SC, Jones DR, Broderick S, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. 2018;378:1976–86. doi:10.1056/NEJMoa1716078.
   PubMed Web of Science ®Google Scholar
• Rs H, Jc S, Kowanetz M, Gd F, Hamid O, Ms G, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563–67. doi:10.1038/nature14011.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823–33. doi:10.1056/NEJMoa1606774.
   PubMed Web of Science ®Google Scholar
• Su S, Hu B, Shao J, Shen B, Du J, Du Y, Zhou J, Yu L, Zhang L, Chen F, et al. CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients. Sci Rep. 2016;6:20070. doi:10.1038/srep20070.
   PubMed Web of Science ®Google Scholar
• Rupp LJ, Schumann K, Roybal KT, Gate RE, Ye CJ, Lim WA, Marson A. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci Rep. 2017;7:737. doi:10.1038/s41598-017-00462-8.
   PubMed Web of Science ®Google Scholar
• Mirzaei HR, Rodriguez A, Shepphird J, Brown CE, Badie B. Chimeric antigen receptors t cell therapy in solid tumor: challenges and clinical applications. Front Immunol. 2017;8:1850. doi:10.3389/fimmu.2017.01850.
   PubMed Web of Science ®Google Scholar
• Turnis ME, Andrews LP, Vignali DA. Inhibitory receptors as targets for cancer immunotherapy. Eur J Immunol. 2015;45:1892–905. doi:10.1002/eji.201344413.
   PubMed Web of Science ®Google Scholar
• Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 2010;207:2187–94. doi:10.1084/jem.20100643.
   PubMed Web of Science ®Google Scholar
• Odorizzi PM, Wherry EJ. Inhibitory receptors on lymphocytes: insights from infections. J Immunol. 2012;188:2957–65. doi:10.4049/jimmunol.1100038.
   PubMed Web of Science ®Google Scholar
• Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158–68. doi:10.1056/NEJMra1703481.
   PubMed Web of Science ®Google Scholar
• Eyquem J, Mansilla-Soto J, Giavridis T, van der Stegen SJ, Hamieh M, Cunanan KM, Odak A, Gönen M, Sadelain M. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature. 2017;543:113–17. doi:10.1038/nature21405.
   PubMed Web of Science ®Google Scholar
• Roth TL, Puig-Saus C, Yu R, Shifrut E, Carnevale J, Li PJ, Hiatt J, Saco J, Krystofinski P, Li H, et al. Reprogramming human T cell function and specificity with non-viral genome targeting. Nature. 2018;559:405–09. doi:10.1038/s41586-018-0326-5.
   PubMed Web of Science ®Google Scholar
• Williams MR, Fricano-Kugler CJ, Getz SA, Skelton PD, Lee J, Rizzuto CP, Geller JS, Li M, Luikart BW. A retroviral CRISPR-Cas9 system for cellular autism-associated phenotype discovery in developing neurons. Sci Rep. 2016;6:25611. doi:10.1038/srep25611.
   PubMed Web of Science ®Google Scholar
• Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelson T, Heckl D, Ebert BL, Root DE, Doench JG, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2014;343:84–87. doi:10.1126/science.1247005.
   PubMed Web of Science ®Google Scholar
• Ran FA, Cong L, Yan WX, Scott DA, Gootenberg JS, Kriz AJ,  Zetsche B, Shalem O, Wu X, Makarova KS, et al. In vivo genome editing using staphylococcus aureus Cas9. Nature. 2015;520:186–91. doi:10.1038/nature14299.
   PubMed Web of Science ®Google Scholar
• Swiech L, Heidenreich M, Banerjee A, Habib N, Li Y, Trombetta J, Sur M, Zhang F. In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nat Biotechnol. 2015;33:102–06. doi:10.1038/nbt.3055.
   PubMed Web of Science ®Google Scholar
• Kim S, Kim D, Cho SW, Kim J, Kim JS. Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res. 2014;24:1012–19. doi:10.1101/gr.171322.113.
   PubMed Web of Science ®Google Scholar
• Schumann K, Lin S, Boyer E, Simeonov DR, Subramaniam M, Gate RE, Haliburton GE, Ye CJ, Bluestone JA, Doudna JA, et al. Generation of knock-in primary human T cells using Cas9 ribonucleoproteins. Proc Natl Acad Sci U S A. 2015;112:10437–42. doi:10.1073/pnas.1512503112.
   PubMed Web of Science ®Google Scholar
• Seki A, Rutz S. Optimized RNP transfection for highly efficient CRISPR/Cas9-mediated gene knockout in primary T cells. J Exp Med. 2018;215:985–97. doi:10.1084/jem.20171626.
   PubMed Web of Science ®Google Scholar
• Mandal PK, Ferreira LM, Collins R, Meissner TB, Boutwell CL, Friesen M, Vrbanac V, Garrison BS, Stortchevoi A, Bryder D, et al. Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9. Cell Stem Cell. 2014;15:643–52. doi:10.1016/j.stem.2014.10.004.
   PubMed Web of Science ®Google Scholar
• Hsu PD, Scott DA, Weinstein JA, Ran FA, Konermann S, Agarwala V, Li Y, Fine EJ, Wu X, Shalem O, et al. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol. 2013;31:827–32. doi:10.1038/nbt.2647.
   PubMed Web of Science ®Google Scholar
• Cho SW, Kim S, Kim Y, Kweon J, Kim HS, Bae S, Kim J-S. Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases. Genome Res. 2014;24:132–41. doi:10.1101/gr.162339.113.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Kim E, Kim JS. Targeted chromosomal deletions in human cells using zinc finger nucleases. Genome Res. 2010;20:81–89. doi:10.1101/gr.099747.109.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Kweon J, Kim E, Kim S, Kim JS. Targeted chromosomal duplications and inversions in the human genome using zinc finger nucleases. Genome Res. 2012;22:539–48. doi:10.1101/gr.129635.111.
   PubMed Web of Science ®Google Scholar
• Kosicki M, Tomberg K, Bradley A. Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements. Nat Biotechnol. 2018;36:765–71. doi:10.1038/nbt.4192.
   PubMed Web of Science ®Google Scholar
• Shin HY, Wang C, Lee HK, Yoo KH, Zeng X, Kuhns T, Yang CM, Mohr T, Liu C, Hennighausen L. CRISPR/Cas9 targeting events cause complex deletions and insertions at 17 sites in the mouse genome. Nat Commun. 2017;8:15464. doi:10.1038/ncomms15464.
   PubMed Web of Science ®Google Scholar
• Kleinstiver BP, Prew MS, Tsai SQ, Topkar VV, Nguyen NT, Zheng Z, Gonzales APW, Li Z, Peterson RT, Yeh J-RJ, et al. Engineered CRISPR-Cas9 nucleases with altered PAM specificities. Nature. 2015;523:481–85. doi:10.1038/nature14592.
   PubMed Web of Science ®Google Scholar
• Gasiunas G, Barrangou R, Horvath P, Siksnys V. Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc Natl Acad Sci U S A. 2012;109:E2579–E2586. doi:10.1073/pnas.1208507109.
   PubMed Web of Science ®Google Scholar
• Kleinstiver BP, Pattanayak V, Prew MS, Tsai SQ, Nguyen NT, Zheng Z, Joung JK. High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature. 2016;529:490–95. doi:10.1038/nature16526.
   PubMed Web of Science ®Google Scholar
• Fu Y, Sander JD, Reyon D, Cascio VM, Joung JK. Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat Biotechnol. 2014;32:279–84. doi:10.1038/nbt.2808.
   PubMed Web of Science ®Google Scholar
• Mollanoori H, Shahraki H, Rahmati Y, Teimourian S. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment. Hum Immunol. 2018. doi:10.1016/j.humimm.2018.09.007.
   PubMed Web of Science ®Google Scholar
• Kimberland ML, Hou W, Alfonso-Pecchio A, Wilson S, Rao Y, Zhang S, Lu Q. Strategies for controlling CRISPR/Cas9 off-target effects and biological variations in mammalian genome editing experiments. J Biotechnol. 2018;284:91–101. doi:10.1016/j.jbiotec.2018.08.007.
   PubMed Web of Science ®Google Scholar